Promising advances in cancer therapy stemming from an increasing understanding of the molecular and genetic underpinnings of the tumorigenic process have been fueled by a strong, determined scientific community, influential patient advocacy groups and committed funding bodies. Despite these efforts, the development of effective drugs to prevent systemic dissemination of cancer cells or to eliminate overt metastasis in secondary organs remains a challenge to both researchers and physicians. In an attempt to tackle the most relevant and timely translational issues, a meeting held in 2012 as a result of a successful partnership between the Volkswagen Foundation and Nature Medicine brought together a group of metastasis research experts to identify the most important hurdles and help create a framework for potential clinical and translational strategies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
CHFR regulates chemoresistance in triple-negative breast cancer through destabilizing ZEB1
Cell Death & Disease Open Access 30 August 2021
-
Humanized anti-DEspR IgG4S228P antibody increases overall survival in a pancreatic cancer stem cell-xenograft peritoneal carcinomatosis ratnu/nu model
BMC Cancer Open Access 14 April 2021
-
Collagen-rich airway smooth muscle cells are a metastatic niche for tumor colonization in the lung
Nature Communications Open Access 13 May 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Nguyen, D.X., Bos, P.D. & Massague, J. Nat. Rev. Cancer 9, 274–284 (2009).
Fearon, E.R. & Vogelstein, B. Cell 61, 759–767 (1990).
Brabletz, T. et al. Proc. Natl. Acad. Sci. USA 98, 10356–10361 (2001).
Brabletz, T. Nat. Rev. Cancer 12, 425–436 (2012).
Chaffer, C.L. & Weinberg, R.A. Science 331, 1559–1564 (2011).
Dalerba, P., Cho, R.W. & Clarke, M.F. Annu. Rev. Med. 58, 267–284 (2007).
Thiery, J.P., Acloque, H., Huang, R.Y. & Nieto, M.A. Cell 139, 871–890 (2009).
Brabletz, T., Jung, A., Spaderna, S., Hlubek, F. & Kirchner, T. Nat. Rev. Cancer 5, 744–749 (2005).
Mani, S.A. et al. Cell 133, 704–715 (2008).
Pantel, K. & Alix-Panabières, C. Trends Mol. Med. 16, 398–406 (2010).
Aguirre-Ghiso, J.A., Bragado, P. & Sosa, M.S. Nat. Med. 19, 276–277 (2013).
Kreso, A. et al. Science 339, 543–548 (2013).
Korpal, M. et al. Nat. Med. 17, 1101–1108 (2011).
Ocaña, O.H. et al. Cancer Cell 22, 709–724 (2012).
Tsai, J.H., Donaher, J.L. & Murphy, D.A. Cancer Cell 22, 725–736 (2012).
Singh, A. & Settleman, J. Oncogene 29, 4741–4751 (2010).
Stoecklein, N.H. et al. Cancer Cell 13, 441–453 (2008).
Podsypanina, K. et al. Science 321, 1841–1844 (2008).
Joosse, S.A. & Pantel, K. Cancer Res. 73, 8–11 (2013).
Weiss, L. Adv. Cancer Res. 54, 159–211 (1990).
Peinado, H., Lavotshkin, S. & Lyden, D. Semin. Cancer Biol. 21, 139–146 (2011).
Kaplan, R.N. et al. Nature 438, 820–827 (2005).
Crawford, Y. & Ferrara, N. Cell Tissue Res. 335, 261–269 (2009).
Müller, A. et al. Nature 410, 50–56 (2001).
Peinado, H. et al. Nat. Med. 18, 883–891 (2012).
Psaila, B. & Lyden, D. Nat. Rev. Cancer 9, 285–293 (2009).
Paget, S. Lancet 1, 571–573 (1889).
Hanahan, D. & Coussens, L.M. Cancer Cell 21, 309–322 (2012).
Valastyan, S. & Weinberg, R.A. Cell 147, 275–292 (2011).
Rhim, A.D. et al. Cell 148, 349–361 (2012).
Pantel, K. et al. Clin. Chem. 58, 936–940 (2012).
Kang, Y. & Pantel, K. Cancer Cell 23, 573–581 (2013).
Moserle, L. & Casanovas, O. J. Intern. Med. 273, 128–137 (2013).
He, S. et al. J. Pathol. 227, 431–445 (2012).
Chou, J. et al. Nat. Cell Biol. 15, 201–213 (2013).
McMillin, D.W., Negri, J.M. & Mitsiades, C.S. Nat. Rev. Drug Discov. 12, 217–228 (2013).
Levental, K.R. et al. Cell 139, 891–906 (2009).
Erez, N., Truitt, M., Olson, P., Arron, S.T. & Hanahan, D. Cancer Cell 17, 135–147 (2010).
Tan, W. et al. Nature 470, 548–553 (2011).
Allinen, M. et al. Cancer Cell 6, 17–32 (2004).
Loeffler, M., Kruger, J.A., Niethammer, A.G. & Reisfeld, R.A. J. Clin. Invest. 116, 1955–1962 (2006).
Chen, Y. et al. J. Clin. Invest. 123, 2395–2407 (2013).
Nakasone, E.S. et al. Cancer Cell 21, 488–503 (2012).
Kelber, J.A. et al. Cancer Res. 72, 2554–2564 (2012).
Acharyya, S. et al. Cell 150, 165–178 (2012).
Hao, J. et al. PLoS ONE 7, e40716 (2012).
Tenbaum, S.P. et al. Nat. Med. 18, 892–901 (2012).
Houthuijzen, J.M., Daenen, L., Roodhart, J. & Voest, E. Br. J. Cancer 106, 1901–1906 (2012).
Liu, S., Tetzlaff, M., Cui, R. & Xu, X. Am. J. Pathol. 181, 1823–1835 (2012).
Li, P., Lin, Y., Zhang, Y., Zhu, Z. & Huo, K. J. Transl. Med. 11, 52 (2013).
Guerin, E., Man, S., Xu, P. & Kerbel, R. Cancer Res. 73, 2743–2748 (2013).
Ding, Z. et al. Cell 148, 896–907 (2012).
Morton, J.P. et al. Gastroenterology 139, 292–303 (2010).
Marshall, J.C. et al. J. Natl. Cancer Inst. 104, 1306–1319 (2012).
Palmieri, D. et al. Clin. Cancer Res. 15, 6148–6157 (2009).
Kishida, Y., Yoshikawa, H. & Myoui, A. Clin. Cancer Res. 13, 59–67 (2007).
LoRusso, P.M. et al. Clin. Cancer Res. 18, 6101–6109 (2012).
Steeg, P.S. Nature 485, S58–S59 (2012).
Palmieri, D. et al. Cancer Res. 67, 4190–4198 (2007).
Stemmler, H.-J. et al. Anticancer Drugs 18, 23–28 (2007).
Acknowledgements
T.B. is supported by the Deutsche Forschungsgemeinschaft (SFB850, B2 and SFB992, C06) and the Deutsche Krebshilfe (grant 109430).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
P.S.S. receives research funding from Sanofi. The other authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Brabletz, T., Lyden, D., Steeg, P. et al. Roadblocks to translational advances on metastasis research. Nat Med 19, 1104–1109 (2013). https://doi.org/10.1038/nm.3327
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3327
This article is cited by
-
Humanized anti-DEspR IgG4S228P antibody increases overall survival in a pancreatic cancer stem cell-xenograft peritoneal carcinomatosis ratnu/nu model
BMC Cancer (2021)
-
CHFR regulates chemoresistance in triple-negative breast cancer through destabilizing ZEB1
Cell Death & Disease (2021)
-
The peptide mimicking small extracellular ring domain of CD82 inhibits tumor cell migration in vitro and metastasis in vivo
Journal of Cancer Research and Clinical Oncology (2021)
-
Collagen-rich airway smooth muscle cells are a metastatic niche for tumor colonization in the lung
Nature Communications (2019)
-
Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
Acta Neuropathologica Communications (2019)